Format

Send to

Choose Destination
Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors.

Author information

1
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2
Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Seoul, Korea.
3
Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.

Abstract

We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. Simultaneously, FLT3-amplified patient-derived cells (PDCs) were generated to evaluate the sensitivity to FLT3 inhibition. A patient with metastatic colon cancer who was previously treated with more than 3rd line cytotoxic chemotherapy was found to have FLT3 amplification and then received regorafenib showing partial response. In two PDC cell lines with FLT3 amplification, FLT3 mRNA expression was increased, however, the growth of tumor cells was not significantly inhibited by either regorafenib or sorafenib which is known to block the activity FLT3. Additional drug combinations with mTOR inhibitor did not affect the cell proliferation of PDC. FLT3 amplification in solid cancers is infrequently observed using targeted genomic profile, as yet, FLT3 amplification does not seem to be an actionable target or a proper biomarker for FLT3 inhibitor sensitivity.

KEYWORDS:

FLT3 amplification; regorafenib; solid tumors

PMID:
27906677
PMCID:
PMC5356878
DOI:
10.18632/oncotarget.13700
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center